Johan Richter
21 – 30 of 108
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells
(
- Contribution to journal › Article
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article
-
Mark
Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
(
- Contribution to journal › Article
-
Mark
In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
(
- Contribution to journal › Article
-
Mark
Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Regulation and Function of Lentiviral Vector-Mediated TCIRG1 Expression in Osteoclasts from Patients with Infantile Malignant Osteopetrosis : Implications for Gene Therapy
(
- Contribution to journal › Article
-
Mark
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy
(
- Contribution to journal › Article
-
Mark
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
(
- Contribution to journal › Article
-
Mark
Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia
(
- Contribution to journal › Article